UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Here at Page Six Style, we’re constantly chronicling the best red carpet looks at the Grammys, SAG Awards and every ceremony ...

Implores UDF IV Board to Postpone March 4 Special Meeting for One Month to Engage with NexPoint and Appropriately Evaluate Proposal NexPoin ...

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...

Synchrony Financial partners with retailers and medical providers to offer promotional financing as well as private-label and co-branded general-purpose credit cards. While the company’s CareCredit ...

Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key ...

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in ...

Research and Development (R&D) expenses: R&D expenses were $24.8 million for the fourth quarter of 2024, compared to $42.0 million for the fourth quarter of 2023. R&D expenses were $117.0 million for ...

After the global financial crisis of 2007-08 , the UK's banking sector was placed under a much stricter regime. Bonuses were ...

A PEN America study found that over half of the book bans censor marginalized communities.

The J.M. Smucker Co. (NYSE: SJM) today announced results for the third quarter ended January 31, 2025, of its 2025 ...